News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Ipsen’s Full Year 2006 Results
March 19, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
PARIS--(BUSINESS WIRE)--The Board of Directors of Ipsen (Paris:IPN), chaired by Jean-Luc Bélingard, met on 16 March 2007 to review the Group’s full year 2006 results published today.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
Ipsen Biopharmaceuticals, Inc.
MORE ON THIS TOPIC
Earnings
Novo Execs Face Skeptical Analysts Amid Metsera Buyout Drama
November 5, 2025
·
5 min read
·
Annalee Armstrong
Podcast
Pfizer and Novo Battle Over Metsera, Tidmarsh Fights FDA Exit, UniQure and Sarepta Face Setbacks
November 5, 2025
·
1 min read
·
Heather McKenzie
Rare diseases
Biohaven Cuts R&D Spending by 60% After FDA Rejection of Drug for Rare Neurodegenerative Disease
November 5, 2025
·
2 min read
·
Tristan Manalac
Preclinical
Arena BioWorks Folds Less Than Two Years After Launch, Blames ‘Policy Uncertainty’
November 5, 2025
·
2 min read
·
Tristan Manalac
